Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

UCSan Deigo School of Medicine.pdf

A poster presentation delivered by Professor Dwayne Stupack from the University of California, San Diego at the AACR Special Conference in Cancer Research:  Ovarian Cancer has shared the findings of new preclinical studies that support the potential of our FAK inhibitor, narmafotinib (AMP945), in the treatment of high-grade serous ovarian cancer.

The data shows that narmafotinib is active in mouse models of ovarian cancer, with improved activity and tolerability compared to PARP inhibitors - the current standard-of-care. Furthermore, it shows promising activity in a model unresponsive to these inhibitors. This builds on Prof. Stupack's previous research demonstrating that inhibition of the FAK enzyme can make chemotherapy and immunotherapy more effective in tough-to-treat ovarian cancers.

Each year over 1000 women in Australia die from ovarian cancer, indicating a clear need for better treatments.

Amplia CEO and MD, Dr Chris Burns, commented:

“The research results presented today by Prof. Stupack are extremely exciting and clearly demonstrate that our best-in-class FAK inhibitor narmafotinib has significant potential in the treatment of ovarian cancer.”

Click link below to read the full article.

AACR Ovarian Cancer Conference Presentation